Investor Presentation (Revised) - Q1 FY27 Results

August 07, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Investor Presentation (Revised) - Q1 FY27 Results Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose a copy of the Investor Presentation (Revised) on the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026. The above is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a/a LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com Investor Presentation Q1 FY27 August 07, 2026 Safe Harbor Statement Materials and information provided during this presentation may contain forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry, geopolitical and market conditions, domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related forward looking statements. Product risks and uncertainties include, but are not limited to, technological advances, regulatory environment and patents obtained by other pharmaceutical companies. Challenges inherent in new product development include but are not limited to completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and international operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. You are cautioned not to place undue reliance on these forward- looking statements, which reflect our opinions only as of the date of the presentation. Lupin Limited, its directors, officers, employees and affiliates expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Q1 FY27 Performance Q1 FY27 - Key Growth Metrics Continued Strong Operating Performance Key Metrics Business Performance Values in INR unless indicated otherwise APAC India 82,172 mn Sales 3,142 mn | Flat YoY 23,796 mn | 33% YoY 14% YoY LATAM 2,975 mn | 71% YoY 24,635 mn EBITDA1 30.0% North America 50% YoY Margin 35,908 mn | 43% YoY 3,370 mn | 69% YoY 14,150 mn Net Income2 17.2% EMEA 16% YoY MPAaTrgin 10,344 mn | 65% YoY 2,637 mn | 9% YoY 1. EBITDA margin excludes Forex and Other Income on Net Sales as base; Arrows indicate Growth / degrowth 4 2. Net income is after adjusting NCI stake from PAT Q1 FY27 - Key Developments Strong Revenue Growth with Healthy EBITDA Margins Financials Key Launches / Approvals Sales* and EBITDA margin Trajectory Azilsartan Medoxomil Ranibizumab Launched US FDA Tabs (Ranluspec ) In US Approval 82,172 biosimilar (RLD Edarbi®) 80,000 73,919 37.0% 71,005 68,314 Business Development 70,000 61,638 32.0% 60,000 • Received EMA1 Approval to extend NaMuscla® for children aged 6–17 years, 31.3% 31.1% including two new age & weight appropriate strengths 30.0% 50,000 29.4% 27.0% • China approval for Oseltamivir Phosphate oral suspension in partnership with 26.6% 40,000 Yabao Pharmaceuticals marking Lupin’s first entry into the market 22.0% 30,000 • Launched Luforbec® (beclometasone/formoterol) MDI in strategic partnership with Laboratorios ERN S.A. in Spain 20,000 17.0% • LNP8701 (novel SOS1 inhibitor2) Phase 1a data accepted for publication at 10,000 ASCO 2026, reinforcing Lupin’s oncology innovation pipeline 0 12.0% Compliance Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 US FDA Others Sales* EBITDA margin** • Ankleshwar & Somerset: EIR received • Nagpur Unit I & II : Approval *excludes Other Operating Income ** EBITDA margins exclude Fx and Other Income on Net Sales as base with VAI status received from HLfGP3 (Germany) • Pithampur Unit II (OAI): response • Ankleshwar: CDSCO approval submitted; remediation in progress received Note: 1. European Medicines Agency | 2. Son of Sevenless1 | 3. Hessisches Landesamt für Gesundheit und Pflege (HLfGP) 5 Q1 FY27: Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) Q1 FY27 Q1 FY26 Q4 FY26 India, 23,796 United States, 34,3481 82,172 61,638 73,919 Sales API, 2,637 24,635 16,414 21,710 EBITDA3 Emerging Markets2, 9,897 Other Developed 12% Net Income4 14,150 12,191 14,604 Markets3, 11,494 1. United States sales includes IP income 2. Other Developed Markets comprises of Canada, Australia, Europe & Others; Emerging Markets comprises of LATAM, South Africa, Philippines & RoW 3. EBITDA excludes Fx and Other income 4. Net income is after adjusting NCI stake from PAT India: Focus on outperforming market growth India business grew 13.9%1 YoY Leveraging Chronic Leadership Brief Overview Brief Overview India Sales (INR mn) #2 #3 #3 Rank Rank Rank 23,796 Respiratory2 Cardiac2 Diabetes Care2 20,894 20,777 20,387 19,082 • Chronic growth 21.5% in Q1 (vs IPM growth of 16.8%3 ) • Chronic share ~67% in Q1 vs ~65% in FY26 • Volume growth of 6.1% in Q1 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 • Total sales force ~11,300 (includes total MRs ~8,700)5 Healthy launches across therapies in FY27 Double digit growth & IPM outperformance in Rx • India Rx business grew by 15.1%4 in Q1 (vs IPM growth of ~13.53%) 3 2 1 1 in GI in Respiratory in Gynae in Anti-Infectives • Key segments – Anti-Diabetes(1.8x) & Cardiology(1.2x) grew faster than market during Q14,3 • Lupisert ranked # 2 in new launch in CNS6 • Anti-diabetes segment grew 31.8%4 vs IPM growth of 17.3%3 in Q1 • Launched 7 products in Q1FY27 • In-licensed % of India Rx sales4: ~6% in Q1, in line with FY26 • Plan to launch 20+ products in FY27 1. India business comprises of Rx + OTC+ Diagnostics +Others Sales data | 2 IQVIA MAT June’26 | 3. IQVIA Qtr June’26 | 4. MIS data | 5. Total Sales Force represents India Formulations field force and related MR’s | 6. IQVIA New Introductions 12 months India: Focus on outperforming market growth IRF poised to outperform IPM by 1.2-1.3x with key drivers in place Enabling end to end healthcare ecosystem & access for the patient Enhancing penetration and reach • CHC Portfolio catering to GI, VMS, Cough/cold therapies • Maximizing Chronic focus with ~70% share by FY31 • Business grew ~14% YoY with highest quarterly l sales in last six quarters • Dedicated division for Semaglutide across a Diabetology/Endocrinology & Gastroenterology/Gynecology i e • Diagnostics platform expanding across India • Build emerging therapies s serving around 7+ lakh patients during quarter • Target Alliances/M&A/inorganic activities – mid size companies, n brands & portfolios u • Beyond the pill approach with digital offering for cardiac patients (~10,000 patients Innovative Product Pipeline onboarded during quarter) & Neuro-rehab • In-house pipeline of innovative assets & biosimilars • In-license new products via partnerships including GLP-1s • Building capacity of HCPs and empowering g patients by impr [Showing first 8,000 characters — download PDF for full document]